The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

A pretreatment step could help transplanted pancreatic islets survive longer in patients with type 1 diabetes, according to a ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

BERKELEY HEIGHTS, NJ, USA and SHANGHAI, China I June 23, 2025 I Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

The dinitrogen molecule, which was first identified in the late 18th century, owes its extreme stability to its triple bond. Therefore, whereas atoms like carbon can exist in multiple allotropes, no ...

Background Shorter half-life glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying (DGE) more than GLP-1 RAs with longer half-lives. DGE is a known risk factor for ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.